Objective
Recent encouraging clinical results obtained with engineered T lymphocytes and increasing advances in the genome editing
field, have opened new opportunities for T-cell receptor (TCR) gene therapy as an immunotherapeutic approach for cancer.
Unfortunately, the broad applicability of this treatment is still hampered by the possible mispairing of exogenous/endogenous
TCR chains and by the limited number of high avidity tumor-specific TCRs. While the first issue has been successfully
addressed by the hosting lab with the development a TCR gene editing protocol, the identification of novel tumor-specific
TCRs is urgently required and this is the aim of my research proposal. We have the unique opportunity to combine the highly
complementary expertise of the hosting lab in T-cell biology/genetic transfer and of the applicant on immune repertoire
sequencing. We will target acute myeloid leukemia (AML) and hypothesize that by exploiting intrinsic features of AML (i.e.
ability of AML blasts to differentiate into potent antigen presenting cells expressing tumor antigens), the functional fingerprint
induced by AML on tumor-reactive T-cells, and cutting-edge technologies (i.e. next generation sequencing; ligandome
landscape analysis), we will provide a comprehensive immunoprofiling of tumor-specific T-cells and isolate tumor TCR
specificities. Results obtained in this study will streamline TCR hunting studies in solid tumors, leading to the generation of a
TCR library for different antigens and HLA restrictions, thus rendering TCR gene editing an innovative off-the-shelf
treatment available for a high number of cancer patients. Awarding this fellowship will greatly enhance researcher’s career
not only by providing the opportunity to widen scientific knowhow and acquire new skills, but also by enabling the researcher
to address a major bottleneck currently limiting the full exploitation of the rapidly growing field of cancer immunotherapy.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences medical biotechnology genetic engineering gene therapy
- medical and health sciences basic medicine immunology immunotherapy
- medical and health sciences clinical medicine oncology leukemia
- natural sciences biological sciences genetics genomes
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-SE - Society and Enterprise panel
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2016
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
20132 Milano
Italy
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.